Skip to main content

09-02-2022 | COVID-19 | News

News in brief

PALLAS data provide reassurance on CDK4/6 inhibitor use during COVID-19 pandemic

Author: Shreeya Nanda


medwireNews: An analysis of the phase 3 PALLAS trial has shown no significant increase in SARS-CoV-2 test positivity and symptomatic infection with the adjuvant use of the CDK4/6 inhibitor palbociclib alongside endocrine therapy (ET) in patients with early breast cancer.

“These data provide reassurance about the safety of using palbociclib in breast cancer treatment during the COVID-19 pandemic,” write Erica Mayer (Dana-Farber Cancer Institute, Boston, Massachusetts, USA) and co-workers in a comment published in The Lancet Oncology.

Of the 5125 participants who remained on study, 721 underwent COVID-19 testing between December 2019 and November 2020, and 12.2% had a positive result.

The rates were comparable between the palbociclib plus ET and ET alone groups, at 11.3% of 362 tested patients and 13.1% of 359, respectively.

Symptomatic infections occurred in 64.8% of the 88 COVID-19-positive patients, with once again no significant difference between patients who did versus did not receive palbociclib, at corresponding rates of 68.3% and 61.7%.

There was one death due to COVID-19 in the palbociclib plus ET group and two in the ET alone group.

“As no COVID-19 vaccination programme was active during the data collection timeframe, the impact of vaccination on the rates of infection could not be addressed in this investigation, but could be considered in a future analysis,” conclude Mayer et al.

medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

09 February 2022: The coronavirus pandemic is affecting all healthcare professionals across the globe. Medicine Matters’ focus, in this difficult time, is the dissemination of the latest data to support you in your research and clinical practice, based on the scientific literature. We will update the information we provide on the site, as the data are published. However, please refer to your own professional and governmental guidelines for the latest guidance in your own country.

Lancet Oncol 2022; doi:10.1016/S1470-2045(21)00708-7